ARS Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ARS Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
ARS Pharmaceuticals: 4 sponsored US clinical trials, 2 recruiting.
ARS Pharmaceuticals sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urticaria Chronic, with 1 trials.
Upper-quartile sponsor footprint
ARS Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
NCT06927999
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
NCT06834165
Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares
NCT05496465
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
NCT05363670
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the ARS Pharmaceuticals pipeline
2 recruiting of 4 indexed (50% open); 2 completed (50%).
Phase mix: 1 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Urticaria Chronic (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ARS Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
ARS Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this ARS Pharmaceuticals page
4 registered trials is a research-attention snapshot, not an endorsement of ARS Pharmaceuticals or any single study.
- 2 of ARS Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Urticaria Chronic is the condition ARS Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urticaria Chronic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ARS Pharmaceuticals pipeline card: 4 registered trials from official public datasets.Report a data error.